RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,105 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,105 shares of the business’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $50.09, for a total transaction of $155,529.45. Following the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $2,116,102.14. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total value of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Price Performance

RxSight stock opened at $50.47 on Friday. The stock has a market capitalization of $1.87 billion, a PE ratio of -40.06 and a beta of 1.20. The business has a 50 day simple moving average of $52.12 and a 200-day simple moving average of $53.82. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $34.89 million for the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The firm’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.40) EPS. On average, equities research analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Institutional Trading of RxSight

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC lifted its stake in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after buying an additional 371 shares in the last quarter. Quest Partners LLC purchased a new position in shares of RxSight in the second quarter valued at approximately $41,000. Larson Financial Group LLC acquired a new stake in shares of RxSight in the first quarter worth approximately $51,000. Amalgamated Bank boosted its stake in shares of RxSight by 21.3% in the second quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of RxSight during the second quarter worth approximately $156,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on RXST. Wells Fargo & Company reduced their price objective on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Stifel Nicolaus reduced their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. BTIG Research upped their price objective on RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Oppenheimer cut their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $60.14.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.